ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray. 

INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses primarily enter, enabling the body to respond more quickly when challenged.  

INNA-051 therapy aims to reduce the incidence of complications in patients at higher risk of severe illness. 

The ‘POSITS’ study is evaluating the safety, tolerability and efficacy of up to three months’ treatment with INNA-051 and assessing its impact on the incidence, duration and severity of symptomatic infections caused by common respiratory viruses in young adult participants at risk of illness due to living or working in crowded environments. 

Part A of the study was successfully completed in 200 participants in May with no safety concerns identified following four weeks of weekly dosing. 

Part B will recruit up to 900 participants during this North American respiratory virus season, with participants dosed for three months across five sites in the US.  

Recruitment will continue to target those in severely crowded households, residents of university housing, military personnel living in barracks, childcare centre workers and/or those living with or caring for a child aged 10 or less attending school or day care. 

ENA Respiratory’s Consultant Medicine Development Lead, Ruth Tal-Singer, said: “The start of large Part B of our study is another important milestone in the development of INNA-051. Complications from respiratory viral infections continue to place a huge burden on patients and healthcare systems globally. By boosting the body’s natural host defence pathways, we believe INNA-051 could offer new hope to millions of vulnerable patients worldwide and we look forward to adding to the clinical evidence of its potential through this study.”